医学
血糖性
优势比
糖化血红素
糖尿病
内科学
减肥
胰腺癌
置信区间
重量变化
胃肠病学
体质指数
病例对照研究
癌症
2型糖尿病
内分泌学
肥胖
作者
Alexandra M. Mueller,Christoph Meier,Susan S. Jick,Cornelia Schneider
出处
期刊:Pancreas
[Ovid Technologies (Wolters Kluwer)]
日期:2018-07-03
卷期号:47 (7): 807-815
被引量:17
标识
DOI:10.1097/mpa.0000000000001085
摘要
Objectives The aim of this study was to characterize the role of glycemic control and weight change as markers for pancreatic cancer (PaC) in patients with long-standing diabetes. Methods We conducted case-control analyses in patients with long-standing diabetes (>2 years) in the United Kingdom–based Clinical Practice Research Datalink. Cases were patients with PaC matched to control subjects on variables including age, sex, and diabetes duration. We compared glycated hemoglobin (HbA 1c ) levels, blood glucose levels, and weight change before cancer detection (matched date) between cases and control subjects to assess associations between the potential markers and PaC. Results Cases were more likely than control subjects to have high HbA 1c levels. The adjusted odds ratio (aOR) was 4.94 (95% confidence interval [CI], 3.52–6.94) for HbA 1c of 64.0 mmol/mol or greater compared with HbA 1c of 47.5 mmol/mol or less within 6 months before cancer detection and within >1 to 2 years, 2.66 (95% CI, 2.00–3.54). Weight loss was also more common in cases, with an aOR of 15.40 (95% CI, 10.65–22.26) for loss of 15.0% body weight or greater compared with stable weight. The aOR for patients with both weight loss of 15.0% or greater and high HbA 1c at 2 years or less before diagnosis was 60.97 (95% CI, 35.87–103.65), compared with patients with neither. Conclusions Poor glycemic control and weight loss, particularly in combination, may be useful early markers for PaC in patients with long-standing diabetes.
科研通智能强力驱动
Strongly Powered by AbleSci AI